Cancer Advances, Inc. Announces the Publication “Gastrin

0

DURHAM, North Carolina, December 06, 2021 (GLOBE NEWSWIRE) – Cancer Advances, Inc., a clinical-stage biopharmaceutical company developing treatments for gastrointestinal cancers, announces a new publication in Frontiers in Oncology, Gastrointestinal Cancers section : Gastric & Oesophageal Cancers.

The gastrointestinal peptide gastrin has been shown to stimulate the growth of gastric cancer through the cholecystokinin-B receptor (CCK-BR), a receptor which is expressed in at least 56.6% of human gastric cancers. Researchers evaluated the effects of Polyclonal Antibody Stimulator (PAS), a phase 3-ready cancer vaccine that induces antibodies against gastrin, alone or in combination with a Programed Death-1 (PD-1 Ab) antibody in mice. immunocompetent carrying YTN-16 gastric tumors.

  • Tumor growth was significantly slower than controls in mice treated with PAS, and the rate of tumor growth was further decreased in mice treated in combination.
  • There was no metastasis in any of the mice treated with PAS alone or in combination with PD-1 Ab.
  • PAS as monotherapy or in combination with PD-1 Ab increased tumor CD8 + T cells and decreased the number of tumor-associated M2 polarized immunosuppressive macrophages.
  • PAS as monotherapy or in combination with PD-1 Ab significantly decreased fibrosis in the tumor microenvironment.

These results show that adding PAS to therapy with an immune checkpoint antibody can decrease gastric cancer growth and metastasis by altering the tumor microenvironment and disrupting the autocrine pathway between gastrin and the CCKB receptor.

The study was conducted in collaboration with the senior author of the manuscript, Jill P. Smith, MD, professor of medicine and oncology at Georgetown University Medical Center, under a sponsored agreement with Cancer Advances, Inc. Cancer Advances is considering seeking approval for PAS for the treatment of gastric and pancreatic cancers.

Link to the publication:

https://www.frontiersin.org/articles/10.3389/fonc.2021.788875/full

About Cancer Advances, Inc.

Cancer Advances Inc. (Durham, North Carolina) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has an extensive intellectual property portfolio.

About the Polyclonal Antibody Stimulator (PAS)

Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in several types of cancer, including gastric, pancreatic and colorectal. The vaccine is a peptide conjugate which comprises an N-terminal human gastrin-17 epitope (G17) linked to the carrier diphtheria toxoid. PAS has been studied in several clinical trials, involving over 1,500 subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and funds and manages all aspects of the PAS gastrin vaccination program.

Contact

Cancer Advances, Inc.
Email: [email protected]
https://www.canceradvances.com/
https://www.linkedin.com/company/cancer-advances/

Share.

Comments are closed.